Affordable Access

deepdyve-link
Publisher Website

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

Authors
  • Steg, Ph Gabriel1
  • Mehta, Shamir R
  • Jukema, J Wouter
  • Lip, Gregory Y H
  • Gibson, C Michael
  • Kovar, Frantisek
  • Kala, Petr
  • Garcia-Hernandez, Alberto
  • Renfurm, Ronny W
  • Granger, Christopher B
Type
Published Article
Journal
European Heart Journal
Publisher
Oxford University Press
Publication Date
October 2011
Volume
32
Issue
20
Pages
2541–2554
Identifiers
DOI: 10.1093/eurheartj/ehr334
PMID: 21878434
Source
Medline
License
Unknown

Abstract

Darexaban when added to dual antiplatelet therapy after ACS produces an expected dose-related two- to four-fold increase in bleeding, with no other safety concerns but no signal of efficacy. Establishing the potential of low-dose darexaban in preventing major cardiac events after ACS requires a large phase III trial. ClinicalTrials.gov Identifier: NCT00994292.

Report this publication

Statistics

Seen <100 times